The Effect of Fasudil on Vascular Function in Humans

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00120718

Enrollment

Registered

2005-07-19

Start date

2002-06-30

Completion date

2007-01-31

Last updated

2008-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Hypercholesterolemia

Brief summary

The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.

Interventions

DRUGfasudil

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Coronary artery disease * Hyperlipidemia -OR- * Healthy adults

Exclusion criteria

* Unstable angina, myocardial infarction or revascularization within 3 months * Symptomatic heart failure * Creatinine \> 3.0 mg/dl * Liver enzymes \> 3X upper limit of normal * Chronic hypoxia * Significant anemia * Chronic inflammatory disease * Pregnancy * Willing to withdraw statins for duration of study

Design outcomes

Primary

Measure	Time frame
Vascular reactivity	—

Secondary

Measure	Time frame
Rho kinase expression	—
Rho kinase activity	—
eNOS expression	—
eNOS activity	—
inflammatory markers	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026